|
WO2021046246A1
|
|
Conjugated hepcidin mimetics
|
|
US2021009638A1
|
|
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
WO2021007433A1
|
|
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
WO2020198682A1
|
|
METHODS FOR SYNTHESIZING β-HOMOAMINO ACIDS
|
|
WO2020014646A1
|
|
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
WO2019157268A1
|
|
Conjugated hepcidin mimetics
|
|
CA3073806A1
|
|
Opioid agonist peptides and uses thereof
|
|
EP3570864A1
|
|
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US2020064357A1
|
|
Methods for determining and monitoring gastrointestinal inflammation
|
|
US2019270786A1
|
|
Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
|
|
WO2018022917A1
|
|
Disulfide-rich peptide libraries and methods of use thereof
|
|
CN109195618A
|
|
Method for synthesizing 4 β of α, 7 peptide antagonists
|
|
WO2017117411A1
|
|
Analogues of hepcidin mimetics with improved in vivo half lives
|
|
US2019300590A1
|
|
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
EA035733B1
|
|
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US2018105572A1
|
|
Cyclic monomer and dimer peptides having integrin antagonist activity
|
|
KR20170108936A
|
|
NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
|
|
US2016145306A1
|
|
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
|
|
EP3161164A2
|
|
Hepcidin and mini-hepcidin analogues and uses therof
|
|
WO2015176035A1
|
|
α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
|
